glp-1 drug exposure pharmaceutical companies 2025 Chart: 1 in 8 Americans Now Use Drugs for Weight Loss Lilly is now pharma's top
Description
However, semaglutide's liver effects are largely indirect, mediated through weight loss and improved metabolic parameters rather than direct hepatic lipid oxidation
In September 2025, Pfizer announced plans to acquire Metsera and its next-generation obesity portfolio
PLoS Genet 19 , e1010710 (2023)
Therefore, this compound seems to be not solely a new antidiabetic medication
Readers are encouraged to verify all details directly with Patchie and their healthcare provider before making decisions
